• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Successful use of guselkumab in the treatment of severe hidradenitis suppurativa.

作者信息

Kearney N, Byrne N, Kirby B, Hughes R

机构信息

Department of Dermatology, St Vincent's University Hospital, Dublin, Ireland.

Charles Institute of Dermatology, University College Dublin, Dublin, Ireland.

出版信息

Clin Exp Dermatol. 2020 Jul;45(5):618-619. doi: 10.1111/ced.14199. Epub 2020 Mar 30.

DOI:10.1111/ced.14199
PMID:32068912
Abstract
摘要

相似文献

1
Successful use of guselkumab in the treatment of severe hidradenitis suppurativa.古塞库单抗成功用于治疗重度化脓性汗腺炎。
Clin Exp Dermatol. 2020 Jul;45(5):618-619. doi: 10.1111/ced.14199. Epub 2020 Mar 30.
2
Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease.古塞库单抗治疗化脓性汗腺炎、银屑病和克罗恩病。
J Dermatolog Treat. 2021 Mar;32(2):261-263. doi: 10.1080/09546634.2019.1654067. Epub 2019 Aug 25.
3
Ixekizumab in hidradenitis suppurativa in a psoriatic patient.司库奇尤单抗治疗一名银屑病患者的化脓性汗腺炎
G Ital Dermatol Venereol. 2020 Dec;155(6):788-789. doi: 10.23736/S0392-0488.18.06135-7. Epub 2019 Jan 9.
4
Treatment of severe hidradenitis Suppurativa and Fistulizing Crohn's disease with Guselkumab.古塞库单抗治疗重度化脓性汗腺炎和瘘管性克罗恩病
J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e563-e565. doi: 10.1111/jdv.18033. Epub 2022 Mar 8.
5
Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.一项开放标签、研究者发起的单中心探索性试验，评估抗白细胞介素-17A单克隆抗体司库奇尤单抗用于中度至重度化脓性汗腺炎患者的疗效。
Br J Dermatol. 2019 Sep;181(3):609-611. doi: 10.1111/bjd.17822. Epub 2019 May 12.
6
Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativa.替拉珠单抗治疗中度至重度化脓性汗腺炎
Australas J Dermatol. 2020 Nov;61(4):e488-e490. doi: 10.1111/ajd.13377. Epub 2020 Jul 6.
7
Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure.抗TNF治疗失败后使用布罗达单抗成功治疗顽固性臀部化脓性汗腺炎。
Int J Dermatol. 2020 Jun;59(6):733-735. doi: 10.1111/ijd.14792. Epub 2020 Feb 3.
8
Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: A retrospective bicentric experience.古塞库单抗治疗中度至重度化脓性汗腺炎的有效性及用药剂量：一项双中心回顾性研究经验
Dermatol Ther. 2022 Jul;35(7):e15558. doi: 10.1111/dth.15558. Epub 2022 May 13.
9
In search of therapeutic biomarkers to interleukin-23 antagonism in hidradenitis suppurativa.
Br J Dermatol. 2023 Apr 20;188(5):588-589. doi: 10.1093/bjd/ljad027.
10
Efficacy of adalimumab in recalcitrant hidradenitis suppurativa.阿达木单抗治疗顽固性化脓性汗腺炎的疗效
Eur J Dermatol. 2009 Mar-Apr;19(2):180-1. doi: 10.1684/ejd.2008.0599. Epub 2009 Jan 20.

引用本文的文献

1
Management of tuberculosis risk, screening and preventive therapy in patients with chronic autoimmune arthritis undergoing biotechnological and targeted immunosuppressive agents.接受生物技术和靶向免疫抑制剂治疗的慢性自身免疫性关节炎患者的结核病风险管理、筛查及预防性治疗
Front Immunol. 2025 Feb 3;16:1494283. doi: 10.3389/fimmu.2025.1494283. eCollection 2025.
2
Guselkumab - In Psoriasis and Beyond.古塞库单抗——用于银屑病及其他病症
Dermatol Pract Concept. 2024 Jul 1;14(3):e2024181. doi: 10.5826/dpc.1403a181.
3
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data.
古塞库单抗、司库奇尤单抗和替拉珠单抗治疗化脓性汗腺炎：现有试验及真实世界数据综述
Clin Cosmet Investig Dermatol. 2023 Sep 18;16:2525-2536. doi: 10.2147/CCID.S418748. eCollection 2023.
4
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.化脓性汗腺炎的新兴治疗方法及临床试验概况 第一部分：局部和全身药物治疗
Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4.
5
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.深入了解化脓性汗腺炎的分子发病机制和免疫调节治疗。
Int J Mol Sci. 2023 May 8;24(9):8428. doi: 10.3390/ijms24098428.
6
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.免疫调节药物治疗化脓性汗腺炎：可能性与局限性。
Int J Mol Sci. 2022 Aug 26;23(17):9716. doi: 10.3390/ijms23179716.
7
Innate immunity and microbial dysbiosis in hidradenitis suppurativa - vicious cycle of chronic inflammation.先天性免疫和微生物失调与化脓性汗腺炎-慢性炎症的恶性循环。
Front Immunol. 2022 Jul 28;13:960488. doi: 10.3389/fimmu.2022.960488. eCollection 2022.
8
New and Emerging Targeted Therapies for Hidradenitis Suppurativa.化脓性汗腺炎的新型及新兴靶向治疗方法
Int J Mol Sci. 2022 Mar 29;23(7):3753. doi: 10.3390/ijms23073753.
9
Hidradenitis Suppurativa: Host-Microbe and Immune Pathogenesis Underlie Important Future Directions.化脓性汗腺炎：宿主-微生物与免疫发病机制是重要的未来研究方向的基础。
JID Innov. 2021 Jan 12;1(1):100001. doi: 10.1016/j.xjidi.2021.100001. eCollection 2021 Mar.
10
New perspectives on the treatment of hidradenitis suppurativa.化脓性汗腺炎治疗的新视角。
Ther Adv Chronic Dis. 2021 Nov 23;12:20406223211055920. doi: 10.1177/20406223211055920. eCollection 2021.